[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"frailty-in-older-adults\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:frailty-in-older-adults":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,51,74,102,123,154,176,196],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100629660","optimizing-intrinsic-capacity-for-functional-independence-and-to-impede-frailty-in-older-adults-adaptation-of-the-who-icope-for-healthy-ageing-in-singapore-100629660",false,"NCT07477561","Optimizing INtrinsic Capacity for Functional INdependence and to Impede FrailTY in Older Adults: Adaptation of the WHO-ICOPE for Healthy Ageing in Singapore","INFINITY-ICOPE","Inclusion Criteria: (in Phases 1, 2 and 3):\n\n* Any Singaporean or Permanent Resident (PR) aged 60 years and above\n* Able to provide informed consent (or legally acceptable representative available)\n\nExclusion Criteria (in Phases 1, 2 and 3):\n\n* Non-Singaporeans or non-PRs under 60 years of age\n* Residents of sheltered or nursing homes",true,"ALL","60 Years",{"count":20,"type":21},600,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this intervention study is to screen and identify frailty and decline in intrinsic capacity (physical and mental capacities) in community-dwelling older adults in Singapore, and to evaluate whether early identification and targeted interventions can improve health outcomes and support healthy ageing. The main questions it aims to answer are:\n\n* Can combined frailty and intrinsic capacity screening with targeted interventions prevent or reduce functional decline in older adults, as measured by changes in life space mobility?\n* Will at least 80% of screened older adults adhere to recommended care pathways and interventions?\n* Can this screening and intervention programme demonstrate sustainability through continued community participation and recruitment of new partner organizations beyond the initial implementation phase? The investigators will compare an intervention group (receiving immediate assessment and clinical referrals based on identified needs) to a wait-list control group (receiving the same interventions 12 months later) to see if early intervention leads to better health outcomes and quality of life.\n\nParticipants will:\n\n* Attend 4 study visits over 2 years (at 6-monthly intervals in the first year, with final assessment at end of year 2), each lasting up to 2 hours.\n* Undergo comprehensive screening assessments including mobility, cognition, mental health, hearing, vision, and nutritional status.\n* Receive 2 follow-up phone calls at 3-month and 9-month intervals to monitor progress.\n* If in the intervention group: receive personalized referrals for further care (which may include comprehensive geriatric assessment, primary care reviews, rehabilitation, or dietitian consultations) and guidance on using a mobile health monitoring application.\n* If in the wait-list control group: receive the same interventions after their 3rd study visit (12 months later).",[27,28,29,30],"Frailty in Older Adults","Intrinsic Capacity","Age-related Functional Decline","Healthy Ageing",[32,33,34,35,36,37],"Frailty","Intrinsic capacity decline","Community-dwelling older adults","Age-related functional decline","Healthy ageing","Early identification and management of frailty and functional decline","RECRUITING","2026-04-14",{"date":41,"type":42},"2026-04-17","ACTUAL",{"date":44,"type":42},"2023-07-17",{"date":46,"type":21},"2028-01-15",{"name":48,"class":49},"Sengkang General Hospital","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":50},"100605673","prevalence-of-anticholinergics-in-geriatric-patients-with-acute-functional-deterioration-100605673","NCT07165574","Prevalence of Anticholinergics in Geriatric Patients With Acute Functional Deterioration","Inclusion Criteria:\n\n* patients seen by the Subacute outpatient geriatric clinic at Aalborg University hospital, Denmark, between 2024 and 2025.\n* Consecutive sampling starting with the most recent patient chart and going backwards.\n* Inclusion is based on chart review and all patients are therefore included consecutively.\n\nExclusion Criteria:\n\n* None",{"count":58,"type":21},100,"OBSERVATIONAL","This study investigates the anticholinergic burden on patients seen in the Subacute mobile outpatient geriatric clinic in Aalborg, Denmark, between the years of 2024 and 2025.\n\nThe age demographic in Denmark and multiple other countries is changing rapidly, with more old and very old individuals as a result. As humans become older, they tend to accumulate more illnesses, and the risk of polypharmacy increases. There is a wide selection of medicine that affect the binding of acetylcholine to the muscarinic receptors, which is either the intended function of the pharmacological product or a side effect.\n\nSince there is no built-in feature in computer systems used by doctors to calculate the cumulative anticholinergic burden, it is often not recognized, thus not reflected upon.\n\nThis raises concerns about potential central and peripheral side effects, such as altered mental status, visual disturbances, tachycardia, urinary and fecal retention, dry skin etc.\n\nThe study aims to determine the prevalence of anticholinergics in the last 100 patients seen by the Subacute mobile outpatient geriatric clinic in Aalborg University Hospital. The patients are placed in municipal extended-care facilities. Furthermore, the study will investigate the prevalence of anticholinergic side effects concerning the burden on this population.\n\nThe study is a retrospective chart review of patient charts from the years of 2024 and 2025, analyzing patient characteristics, comorbidities, medication lists, and calculating the anticholinergic burden through the ACB calculator.",[27,62,63],"Functional Decline","Anticholinergic Syndrome","NOT_YET_RECRUITING","2025-09-09",{"date":67,"type":42},"2025-09-10",{"date":69,"type":21},"2025-09-01",{"date":71,"type":21},"2027-01-01",{"name":73,"class":49},"Aalborg University Hospital",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":84,"briefSummary":86,"conditions":87,"keywords":88,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":4},"100604019","phase-1-safety-and-tolerability-study-of-mesenchymal-stem-cells-hexell-2020-in-elderly-subjects-with-mild-to-moderate-frailty-syndrome-100604019","NCT07144072","Safety and Tolerability Study of Mesenchymal Stem Cells, HeXell-2020, in Elderly Subjects With Mild to Moderate Frailty Syndrome","A Phase I, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of HeXell-2020 Administered Intravenously in Elderly Subjects With Mild to Moderate Frailty Syndrome","Inclusion Criteria:\n\nSubjects will be eligible for enrollment in the study only if they meet ALL the following criteria at time of Screening:\n\n1. Subjects aged ≥ 60 through ≤ 85 years old.\n2. Subjects with clinical diagnosis of mild to moderate Frailty Syndrome as assessed by the Investigator with a Clinical Frailty Scale score between 4 to 6.\n3. Subject will not start any new treatment for this condition during the study.\n4. Subjects with body weight between 40 to 90 kg.\n5. Subject is willing to provide written informed consent to participate in the study after reading the informed consent form and the information provided.\n\nExclusion Criteria:\n\nSubjects meeting ANY of the following criteria at time of Screening will be excluded from enrollment:\n\n1. Subjects unwilling or unable to perform any of the assessments required by endpoint analysis.\n2. Subjects who have a diagnosis of any disabling neurologic disorder including, but not limited to: Parkinson's disease, Amyotrophic Lateral Sclerosis, multiple sclerosis, stroke or dementia.\n3. Subjects who have a score on the Mini-Mental State Examination (MMSE) of 24 or below.\n4. Subjects who have a significant comorbid medical condition(s) including, but not limited to:\n\n   1. Severe kidney disease requiring hemodialysis or peritoneal dialysis;\n   2. Advanced liver disease such as severe liver cirrhosis;\n   3. Severe congestive heart failure (NYHA class 3 and 4);\n   4. Severe pulmonary dysfunction, including severe chronic obstructive pulmonary disease stage III or IV (Gold classification)\n5. Subjects who have a clinical history of malignancy within 5 years (i.e., patients with prior malignancy must be disease free for 5 years), except curatively-treated basal cell carcinoma or in situ carcinomas.\n6. Subjects using chronic immunosuppressant therapy, including corticosteroids (\\> 5 mg\u002Fday of prednisone, or equivalent), or TNF-alpha antagonists.\n7. Subjects on chronic immunosuppressive transplant therapy.\n8. Subjects who have participated in another clinical study of new investigational therapies within 6 months prior to screening.\n9. Subjects who have received any other stem cell therapy within 12 months prior to screening.\n10. Subjects with known allergy or hypersensitivity to any component of the formulation and cellular therapies (i.e., penicillin or streptomycin).\n11. Subjects who have a history of drug or alcohol abuse within the past 3 years.\n12. Subjects who are known to be infected with HIV.\n13. Subjects currently in hospital stay.\n14. Subjects who have a significant illness as judged by principal investigator (PI) including, but not limited to:\n\n    1. Psychiatric illness\n    2. Uncontrolled hypertension or hypotension\n    3. Unstable cardiac arrhythmia\n    4. Active Hepatitis B, Hepatitis C infections\n15. Subjects who have any condition that in the opinion of the Principal Investigator limits lifespan to \\\u003C 1 year.\n16. Subjects who have any other condition that, in the opinion of the investigator, may compromise the safety or compliance of the patient or preclude successful completion of the study.","85 Years",{"count":83,"type":21},12,[85],"PHASE1","This is a phase I study to investigate the safety, and Tolerability of HeXell-2020 in Elderly Subjects with Mild to Moderate Frailty Syndrome.\n\nHeXell-2020 is an investigational drug product consisting of allogenic umbilical cord mesenchymal stem cells (UCMSCs) as the drug substance. All enrolled and eligible subjects will receive HeXell-2020 treatment.",[27],[89,90,91],"HeXell-2020","Mesenchymal Stem Cells (MSC)","Frailty Syndrome (FS)","2025-08-28",{"date":94,"type":42},"2025-09-04",{"date":96,"type":21},"2026-01-31",{"date":98,"type":21},"2028-07-31",{"name":100,"class":101},"Hexun Biosciences Co., LTD.","INDUSTRY",{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":22,"phases":111,"briefSummary":112,"conditions":113,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":50},"100581380","chair-bound-exergaming-in-pre-frail-frail-older-adults-in-nursing-home-100581380","NCT06849557","Chair-bound Exergaming in Pre-frail\u002F Frail Older Adults in Nursing Home","Effectiveness of Chair-bound Exergaming on Physical and Cognitive Functions in Pre-frail\u002F Frail Older Adults in Nursing Home: A Pilot Randomized Controlled Trial","Inclusion Criteria:\n\n* older adults aged 60 years or older living in the nursing homes;\n* pre-frail or frail according to the Fried Frailty Phenotypes;\n* ability to understand and execute instructions; and\n* ability to sit unassisted on a chair or in a wheelchair.\n\nExclusion Criteria:\n\n* no controlled medical diagnosed of severe cardiometabolic, respiratory and musculoskeletal disorders;\n* any conditions that hinder the participation of intervention and assessment; and\n* being involved in any other clinical trials.",{"count":110,"type":21},30,[24],"This pilot randomized controlled trial is designed to investigate the effectiveness of chair-bound exergaming on improving physical and cognitive function in pre-frail\u002F frail nursing home residents",[27],"2025-05-09",{"date":116,"type":42},"2025-05-14",{"date":118,"type":42},"2025-04-07",{"date":120,"type":21},"2025-12",{"name":122,"class":49},"Hong Kong Metropolitan University",{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":4,"eligibilityCriteria":129,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":81,"enrollmentInfo":130,"targetDuration":4,"studyType":22,"phases":132,"briefSummary":134,"conditions":135,"keywords":138,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":4},"100588498","phase-2-safety-and-efficacy-of-isomyosamine-in-reducing-inflammation-and-treating-muscle-loss-in-older-adults-after-hip-or-thigh-bone-fractures-100588498","NCT06942182","Safety and Efficacy of Isomyosamine in Reducing Inflammation and Treating Muscle Loss in Older Adults After Hip or Thigh Bone Fractures","Double Blind Placebo-Controlled Parallel Group Study Of Safety And Efficacy Of Isomyosamine In Treating Sarcopenia After Hip Or Femoral Fracture In Gerontological Population","Inclusion Criteria:\n\n1. Age 60 to 85 years of age\n2. Non-complex, non-comminuted fracture of the femoral head, femoral neck, or acetabulum due to an accidental (non-neurologic or cardiovascular) fall\n3. Concomitant medication limited to treatment for chronic conditions\n4. The ability to give informed consent and comply with study procedures\n5. Body weight ≥35 kg\n6. Adequate dietary intake\n7. Potential subjects' intention to avoid reproductive activity will be confirmed\n\n   And one or more of the following criteria:\n8. Previous history frailty or sarcopenia diagnosis using standardized tests;\n9. Positive assessment for frailty or sarcopenia using standardized tests or as per clinician's judgement;\n10. Previous positive assessment for elevated biomarkers of inflammation (serum IL-6 level\\> LOQ, TNFR1 level \\> LOQ, and\u002For TNF-alpha level \\> LOQ)\n\nExclusion Criteria:\n\n1. Receiving immunotherapy for cancer or solid organ transplantation\n2. Complex or comminuted fracture or fracture of multiple long bones\n3. Regular treatment for chronic disease including chronic renal failure, chronic heart failure (CHF) cerebrovascular disease including stroke, rheumatoid arthritis, or polymyalgia rheumatica\n4. Chronic kidney disease (estimated glomerular filtration rate \\[eGFR\\] \\\u003C60 mL\u002Fmin)\n5. Newly (\\\u003C 2 weeks) diagnosed COVID-19\n6. Inability or unwillingness to give written informed consent\n7. History of upper\u002Flower respiratory tract infection, requiring systemic steroids, antibiotics, and or emergency room (ER) visit or urgent care within 6 weeks of screening visit\n8. History of adverse reaction or allergy to TNF inhibitor\n9. History of neurological, hepatic, renal, diabetic mellitus, thyroid disorder, psychiatric, addiction or other medical conditions that may interfere with the interpretation of data or the patient's participation in the study or may increase safety concerns per investigator discretion\n10. Currently under treatment by an anti-TNFα drug, such as adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, and biosimilars\n11. Currently under treatment by an anti-diabetic medication, including glucagon-like peptide-1 (GLP-1) drugs such as semaglutide, or any of metformin, jenuvia, or insulin\n12. Unwillingness or inability to comply with study procedures, including smoking cessation\n13. History of epilepsy or seizure propensity, ataxia, abnormal EEG findings, abnormal brain magnetic resonance image, or other co-morbid neurological conditions\n14. Positive TB test\n15. Patients who are pregnant or breastfeeding",{"count":131,"type":21},60,[133],"PHASE2","This Phase II clinical study investigates the safety and effectiveness of a new drug, Isomyosamine, in patients with sarcopenia or frailty, conditions associated with aging and muscle weakness. Isomyosamine is a promising oral medication that reduces inflammation by targeting cytokines like TNF-α and IL-6, which are linked to these conditions. Previous studies have shown it is well-tolerated and may help improve muscle strength, mobility, and healing after hip fractures. This trial aims to determine its potential benefits in reducing inflammation and improving recovery in elderly patients.",[136,32,137,27],"Sarcopenia in Elderly","Frailty\u002FSarcopenia",[139,32,140,141,142,143,144],"sarcopenia","Hip Fracture","Older population","Gerontological","Femur fracture","Sarcopenia and Frailty","2025-04-16",{"date":147,"type":42},"2025-04-24",{"date":149,"type":21},"2025-05-01",{"date":151,"type":21},"2026-03-01",{"name":153,"class":101},"TNF Pharmaceuticals, Inc.",{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":160,"eligibilityCriteria":161,"healthyVolunteers":11,"sex":17,"minAge":162,"maxAge":4,"enrollmentInfo":163,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":165,"conditions":166,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":50},"100584454","comparison-of-preoperative-frailty-assessment-tools-100584454","NCT06889545","Comparison of Preoperative Frailty Assessment Tools","Evaluation of a Feasible Frailty Assessment Tool for Preoperative Risk Evaluation of Older Patients","PREFAS","Inclusion Criteria:\n\n* 70 years and older\n* scheduled surgery\n* estimated time of surgery 120 Minutes or more\n\nExclusion Criteria:\n\n* insufficient German language skills (for cognitive testing)\n* mental retardation\n* relevant psychiatric disorder (not allowing for cognitive testing)","70 Years",{"count":164,"type":21},584,"Frailty is a significant risk factor for postoperative complications and functional decline. Preoperative assessment of frailty is therefore recommended in all older adults. However, despite the availability of many frailty tools, few have been tested in the preoperative setting and there is little comparison of their predictive value in identifying patients at risk. The aim of this study is to investigate which of the following instruments for determining frailty has the highest predictive power with regard to the occurrence of postoperative complications: Risk Analysis Index, Clinical Frailty Scale, the Groningen Frailty Indicator, the Edmonton Frail Scale and the LUCAS-FI. The aim of this research project is to identify a suitable frailty instrument for preoperative risk stratification of older patients during the premedication visit.",[32,27,137],"2025-03-30",{"date":169,"type":42},"2025-04-03",{"date":171,"type":21},"2025-04-15",{"date":173,"type":21},"2027-10-01",{"name":175,"class":49},"Universitätsklinikum Hamburg-Eppendorf",{"id":177,"slug":178,"hasResults":11,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":4,"eligibilityCriteria":182,"healthyVolunteers":11,"sex":17,"minAge":183,"maxAge":4,"enrollmentInfo":184,"targetDuration":4,"studyType":22,"phases":186,"briefSummary":187,"conditions":188,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":191,"completionDateStruct":192,"leadSponsor":194,"locationsCount":50},"100583338","the-effects-of-intelligent-intervention-programs-on-hospitalized-elderly-people-with-frailty-100583338","NCT06875024","The Effects of Intelligent Intervention Programs on Hospitalized Elderly People With Frailty.","A Series of Studies on Influencing Factors and Intelligent Intervention Programs for Hospitalized Elderly People With Frailty","Inclusion Criteria:\n\n* Hospitalized patients aged 65 years and older. (、\n* Admitted to the nephrology department or undergoing dialysis.\n* Conscious, able to express themselves independently, follow instructions, and communicate in Mandarin or Taiwanese.\n* Expected hospital stay of at least six days.\n* Assessed using the Physical Activity Readiness Questionnaire for Everyone (PAR-Q+) and deemed to have no immediate risk for exercise participation, with normal capability for physical activity.\n\nExclusion Criteria:\n\n* Severe visual or hearing impairments that hinder communication or assessments.\n* Significant cognitive impairment, defined as a Montreal Cognitive Assessment (MoCA) score \\\u003C 24.\n* Patients who do not consent to participate in the study.\n* Individuals unable to personally complete the consent form.\n* Patients receiving palliative care.\n* Regular participants in rehabilitation therapy.\n* Charlson Comorbidity Index (CCI) score ≥ 5.","65 Years",{"count":185,"type":21},156,[24],"Background: As the aging population grows, hospitalized elderly individuals with frailty have become a major concern. Frailty is a complex syndrome linked to aging, marked by dependency and vulnerability. Elderly patients often face chronic diseases, making them more susceptible to frailty. Studies show frailty prevalence in hospitalized elderly patients is 88.7%, and 75.3% among kidney disease patients. Frailty is associated with advanced age, female gender, low body mass index, comorbidities, and poor nutrition, increasing the risks of falls, hospitalization, and mortality. Frail kidney disease patients face worse outcomes. However, frailty is reversible with early intervention. Current treatments, based on comprehensive geriatric assessment (CGA), require significant resources. This study aims to explore frailty prevention and care through research and intervention development.\n\nPurpose: To explore the effectiveness of an intelligent intervention program in improving frailty among hospitalized elderly individuals.\n\nMethods: An experimental research design was adopted. A total of 156 hospitalized elderly patients with kidney disease who met the inclusion criteria were recruited through convenience sampling. Participants were randomly assigned to either the experimental group (n = 78) or the control group (n = 78). The experimental group received a 12-week intelligent intervention program, while the control group received routine care.Subsequently, data on frailty level, daily living function 30 days after discharge, and unexpected readmission rate 30 days after discharge will be collected by researchers and analyzed using SPSS 22.0, including chi-square tests, repeated measures ANOVA, and Generalized Estimating Equations (GEE) for intra-group and inter-group comparisons of each outcome variable.\n\nExpected research results: This study aims to understand the current status and influencing factors of frailty among hospitalized elderly patients with kidney disease and to develop an intelligent intervention program. The goal is to provide clinical nursing staff with a frailty care strategy for hospitalized patients, effectively reducing frailty among elderly inpatients, improving their daily functional ability after discharge, and decreasing hospital readmission rates.\n\nCondition or disease: frailty Intervention\u002Ftreatment: intelligent intervention program",[27],"2025-03-29",{"date":169,"type":42},{"date":171,"type":21},{"date":193,"type":21},"2026-12-31",{"name":195,"class":49},"National Taipei University of Nursing and Health Sciences",{"id":197,"slug":198,"hasResults":11,"nctId":199,"briefTitle":200,"officialTitle":200,"acronym":4,"eligibilityCriteria":201,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":202,"enrollmentInfo":203,"targetDuration":4,"studyType":22,"phases":205,"briefSummary":206,"conditions":207,"keywords":208,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":4},"100573100","a-biopsychosocial-approach-to-improving-multidimensional-frailty-status-in-community-dwelling-older-adults-100573100","NCT06741878","A Biopsychosocial Approach to Improving Multidimensional Frailty Status in Community-Dwelling Older Adults","Inclusion Criteria:\n\n* Age 60 to 80\n* Willing and capable to participate in this study and training\n* Willing and capable to give informed consent to participate in this study\n* Preliminarily classified as physically prefrail\u002Frobust, in that they possess no more than three of the indicators on the Fried Frailty Index (FFI; unintentional weight loss, exhaustion, low physical activity, slow walking speed, weak grip strength; Bieniek et al., 2016)\n* Can walk independently to an elderly centre\n* Have a smartphone for internal group communication and remote interaction with their peers and the instructor\n\nExclusion Criteria:\n\n* History of systematic cardiovascular diseases causing stroke, Parkinson's disease, early stages of Alzheimer's disease, or cognitive impairment\n* Physical injuries or other conditions that would hinder regular attendance and participation in the assessments for the study\n* Concurrent major psychiatric disorder (e.g. major depressive disorder, schizophrenia) or drug and alcohol abuse\n* Unable to handle digital devices\n* Currently undergoing exercise programmes or classified as physically 'very active' (i.e. performing strenuous activity for 5+ hours each week)","80 Years",{"count":204,"type":21},308,[24],"Frailty is a common clinical syndrome that is becoming increasingly important as populations age worldwide. Individuals who are frail are at a higher risk for negative outcomes, such as falls, disability, hospitalizations, and even death. The understanding of frailty has evolved from a straightforward concept to a complex model that includes physical, psychological, cognitive, and social factors. Since frailty is not static and can change over time, early interventions can be beneficial. Nevertheless, research in this area has been challenging due to a lack of agreement on what frailty encompasses and an inadequate understanding of how its different components interact. Defining frailty as a multidimensional issue is essential to recognize the adverse effects that can arise from medical, psychological, and social influences. However, recent studies have not sufficiently addressed how these different aspects work together or developed effective multidimensional interventions.",[27],[209,210,211,212,213,214,215],"Multi-dimensional frailty","Biopsychosocial approach","Exercise training","Nutrition education","Psychosocial support","Older adults","Intervention programs","2024-12-15",{"date":218,"type":42},"2024-12-19",{"date":220,"type":21},"2025-01-01",{"date":222,"type":21},"2026-06-30",{"name":224,"class":49},"Hong Kong Baptist University"]